GRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Guardian Pharmacy Services Inc (GRDN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows mixed signals, with no clear upward momentum in technical indicators, weak financial performance in the latest quarter, and no significant positive catalysts. While the stock has potential for short-term gains, it does not align with the user's long-term investment goals.
The technical indicators are mixed. The MACD is above 0 and positively contracting, suggesting mild bullish momentum. The RSI is neutral at 54.431, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is down 4.16% in regular market trading, and the next month's trend prediction suggests a potential decline of -4.54%. Support and resistance levels indicate the stock is trading near its pivot point of 32.409, with resistance at 34.527 and support at 30.29.
The company has shown revenue growth of 20.05% YoY in Q3 2025, and gross margin increased by 2.27% YoY. Upcoming earnings on February 16, 2026, could provide further insights into the company's performance.
Net income dropped significantly by -108.05% YoY in Q3 2025, and EPS also fell by -108.00% YoY. The stock is currently down 4.16% in regular market trading, and hedge funds and insiders are neutral with no significant trading trends. Additionally, there is no recent congress trading data or influential figure activity on the stock.
In Q3 2025, the company reported revenue growth of 20.05% YoY to $377.43 million. However, net income and EPS both dropped significantly by -108.05% and -108.00% YoY, respectively. Gross margin improved slightly to 19.8%, up 2.27% YoY. The financial performance indicates revenue growth but significant profitability challenges.
No specific analyst rating or price target changes were provided in the data. Wall Street sentiment appears neutral, with no strong pros or cons highlighted for the stock.
